StockData
BioAge Labs, Inc. logo

BioAge Labs, Inc. (BIOA) stock

BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$4.77−0.33 (-6.47%)

Close on Nov 18, 2026Market cap $218.93MP/E –Yield –

BioAge Labs revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

BioAge Labs's revenue for the twelve months ending Jun 30, 2026 was $10.36M, up 168.1% year over year. For fiscal 2025 it was $9.00M.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.00M–
FY2024Dec 31, 2024$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.45M+1.6%
Q1 FY2026Mar 31, 2026$2.77M+91.0%
Q4 FY2025Dec 31, 2025$3.08M–
Q3 FY2025Sep 30, 2025$2.05M–
Q2 FY2025Jun 30, 2025$2.41M–
Q1 FY2025Mar 31, 2025$1.45M–
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0–

More BioAge Labs figures

See a number that looks wrong?